NCT06693648已完成3 期
A Randomized, Double-Blind, Multi-Center, Placebo-Controlled, Trial to Evaluate the Efficacy and Safety of Once Daily Diclofenac Gel AMZ001 in the Treatment of Pain and Symptoms of Knee Osteoarthritis
Amzell11 个研究点 分布在 5 个国家目标入组 549 人开始时间: 2025年2月18日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 549
- 试验地点
- 11
- 主要终点
- Change from baseline in the WOMAC pain sub-score in the target knee at week 2.
研究概览
简要总结
This is a multicenter, randomized, double-blind, placebo-controlled, parallel group, 6-week trial of a formulation of AMZ001 once daily versus placebo once daily.
详细描述
This is a multicenter, randomized, double-blind, placebo-controlled, parallel group, 6-week trial of a formulation of AMZ001 once daily versus placebo once daily. Participants will be evaluated for osteoarthritis by X-ray images of the knees and one knee will be selected for treatment as the target knee. The study gel will be applied directly to that knee throughout the 6 weeks of the study.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 40 Years 至 85 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Participant is able to read and understand the language and content of the study material, understand the requirements for study visits, and is willing to provide information at the scheduled evaluations and appropriate written informed consent has been obtained.
- •Femorotibial osteoarthritis (OA) of the knee, according to the American College of Rheumatology (ACR) clinical and radiographic criteria (Altman et al. 1986)
- •Radiological OA grade 2, or 3 of the target knee, using the Kellgren-Lawrence method (Kellgren & Lawrence 1957) as graded by central, independent reading of X-ray obtained during screening, or on a recent (within 6 months) X-ray image which fulfils the specifications for central reading.
- •Pain score rated on an 11-point numerical rating scale of the target knee of ≥20 and ≤45 out of 50 in response to the WOMAC pain sub-score (5 questions), at the time of screening and baseline.
- •The WOMAC pain sub-score on the target knee must exceed the one on the contralateral knee, regardless of the eligibility of the contralateral knee.
- •At screening Visit 1a, participants report that their typical OA knee pain in one or both knees when not using medication is ≥4 out of
- •Daily OA knee pain diary average numerical rating scale (NRS) score of ≥4 and ≤9 in the target knee, for the 7 days immediately preceding baseline (Day 1). The average calculation is based on the recorded scores during this entire period with a requirement of at least 4 days of data recorded.
- •Women of child-bearing potential must use at least an acceptably effective method of contraception (progestogen-only oral hormonal contraception, where inhibition of ovulation is not the primary mode of action, male or female condom with or without spermicide, cap, diaphragm or sponge with spermicide) from enrolment up to at least 3 months after the study end. Postmenopausal status is defined as being amenorrheic for at least 1 year prior to screening. Sexually active men with a female partner of childbearing potential must agree to use condom from enrolment up to at least 3 months after the study end.
- •Knee pain in the target knee for at least 14 days of the preceding month (periarticular knee pain due to OA and not due to non-OA conditions such as bursitis, tendonitis, etc.) based on participant report.
- •Except for OA, the participant is in reasonably good health as determined by the Investigator.
排除标准
- •Known or suspected hypersensitivity to or previous hypersensitivity reactions to diclofenac or of the excipients in either of the investigational products.
- •Patients in whom asthma, angioedema, urticaria, or acute rhinitis are precipitated by acetylsalicylic acid or other non-steroidal anti-inflammatory drugs (NSAIDs).
- •Any physical impediment to gel application on the target knee.
- •Intra-articular delivery of corticosteroids or hyaluronic acid in the target knee within 6 months of screening or into any other joint within 30 days of screening.
- •High dose (equivalent to > 10 mg of prednisone/day) systemic corticosteroid treatment of more than 14 days during the past 6 months prior to screening.
- •Major surgery/ arthroscopy of the target knee within the previous year prior to screening or aspiration of effusion of the target knee within 12 weeks prior to enrollment.
- •Planned surgery of the target knee within the next 12 months.
- •Use of a currently unapproved investigational drug, device or biologic within 3 months prior to screening.
- •Presence of concomitant non-osteoarthritic disease affecting either knee, such as rheumatoid arthritis, psoriasis, gout or clinically relevant pseudogout, if there is reason to believe that the disease(s) may significantly interfere with the interpretation of the clinical response to the study drug.
- •Perioperative period in the setting of coronary artery bypass graft surgery.
- •Current malignancy or treatment for malignancy within the past five years, with the exception of non-melanoma skin cancer, unless affecting the target knee area, or carcinoma in situ events.
- •Any other abnormal laboratory results or significant medical conditions that the Investigator believes should preclude the participant's participation in the trial.
- •Secondary OA of the target knee, previous procedures or trauma affecting joint homeostasis including total meniscectomy or septic arthritis, or any other serious condition leading to secondary OA of the target knee.
- •Reported incidence of any of the following diseases: known OA of the hip(s) if pain in either or both hip(s) exceeds that of the target knee using the WOMAC hip pain subscore, or presence of significant radicular back pain.
- •Presence of severe pain in either knee, defined as > 45 out of 50 in response to the WOMAC pain sub-score (5 questions), at the time of screening and baseline, regardless of the eligibility of the contralateral knee.
- •Presence of a defined cut-off of pain variability during the screening period of 1.5 out of 10:
- •Pain Numeric Rating Scale (NRS) scores must be recorded for the target knee on at least 4 out of the 7 days immediately preceding baseline (Day 1)
- •Observed standard deviation of the Daily osteoarthritis (OA) knee pain diary average NRS intensity score for 7 days immediately preceding baseline (Day
- •1) must not exceed 1.5
- •Body mass index > 45.0 kg/m
- •Estimated glomerular filtration (eGFR) rate < 30 mL/min using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI 2021) formula.
- •Generalized skin irritation, previous skin reactions upon use of topical NSAIDs, current skin irritation or redness at the planned site of gel application, or significant skin disease including psoriasis, as judged by the investigator.
- •Use of any topical medication on the planned application site within 15 days of the time of randomization.
- •Use of moderate or higher strength of opioid medication for the treatment of pain within 6 weeks before the screening visit.
- •Use of duloxetine, pregabalin, or gabapentin within 4 weeks before the screening visit.
- •History of alcohol or drug abuse within the past year prior to randomization.
- •Pregnant and breastfeeding women are excluded for participation.
研究组 & 干预措施
Placebo gel
Placebo Comparator
干预措施: Placebo gel (Drug)
AMZ001 diclofenac gel
Experimental
干预措施: AMZ001 Diclofenac gel (Drug)
结局指标
主要结局
Change from baseline in the WOMAC pain sub-score in the target knee at week 2.
时间窗: Baseline and Week 2
WOMAC: Western Ontario and McMasters University Osteoarthritis Index Scale: 0-100, 100 being the worse
Change From Baseline in the WOMAC Pain Sub-score in the Target Knee at Week 2.
时间窗: Baseline and Week 2
Change from baseline in the WOMAC pain sub-score in the target knee at week 2. WOMAC: Western Ontario and McMasters University Osteoarthritis Index Participants will answer all of the 5 questions of WOMAC pain sub-score for themselves, using an 11-box numerical rating scale (with categories of 0 to 10), with reference to the past 24 hours. For convenience and ease of interpretation, total WOMAC pain sub-score will be normalized on scales of 0 to 100 points. Scale: 0-100, 100 being the worse
次要结局
- Change from baseline in the WOMAC pain sub-score at week 1, in the target knee(Baseline and Week 1)
- Change from baseline in daily pain at Day 8 using an 11-point Numeric Rating Scale (NRS)(Baseline and Day 8)
- Change from baseline in daily pain at Day 7 using an 11-point Numeric Rating Scale (NRS)(Baseline and Day 7)
- Change from baseline in daily pain at Day 6 using an 11-point Numeric Rating Scale (NRS)(Baseline and Day 6)
- Change from baseline in daily pain at Day 5 using an 11-point Numeric Rating Scale (NRS)(Baseline and Day 5)
- Change from baseline in daily pain at Day 4 using an 11-point Numeric Rating Scale (NRS)(Baseline and Day 4)
- Change from baseline in daily pain at Day 3 using an 11-point Numeric Rating Scale (NRS)(Baseline and Day 3)
- Change from baseline in daily pain at Day 2 using an 11-point Numeric Rating Scale (NRS)(Baseline and Day 2)
- Change from baseline in daily pain at Day 1 using an 11-point Numeric Rating Scale (NRS)(Baseline and Day 1)
- Change From Baseline in the WOMAC Pain Sub-score at Week 1, in the Target Knee(Baseline and Week 1)
- Change From Baseline in Daily Pain at Day 8 Using an 11-point Numeric Rating Scale (NRS)(Baseline and Day 8)
- Change From Baseline in Daily Pain at Day 7 Using an 11-point Numeric Rating Scale (NRS)(Baseline and Day 7)
- Change From Baseline in Daily Pain at Day 6 Using an 11-point Numeric Rating Scale (NRS)(Baseline and Day 6)
- Change From Baseline in Daily Pain at Day 5 Using an 11-point Numeric Rating Scale (NRS)(Baseline and Day 5)
- Change From Baseline in Daily Pain at Day 4 Using an 11-point Numeric Rating Scale (NRS)(Baseline and Day 4)
- Change From Baseline in Daily Pain at Day 3 Using an 11-point Numeric Rating Scale (NRS)(Baseline and Day 3)
- Change From Baseline in Daily Pain at Day 2 Using an 11-point Numeric Rating Scale (NRS)(Baseline and Day 2)
- Change From Baseline in Daily Pain at Day 1 Using an 11-point Numeric Rating Scale (NRS)(Baseline and Day 1)
研究者
研究点 (11)
Loading locations...
相似试验
已完成
3 期
Safety Study of the Potential Inhibitory Effects of Ciclesonide Nasal Aerosol on the Hypothalamic-Pituitary-Adrenal Axis in Subjects 6-11 Years With Perennial Allergic RhinitisPARPerennial Allergic RhinitisNCT01378429Sumitomo Pharma America, Inc.89
终止
2 期
A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed Dose Study Evaluating the Efficacy and Safety of Orvepitant in Subjects With Major Depressive DisorderDepressive Disorder, MajorNCT00880399GlaxoSmithKline328
已完成
3 期
SLV308 for Treatment of Patients With Early Parkinson's DiseaseEarly Stage Parkinson's DiseaseNCT00269516Solvay Pharmaceuticals468
已完成
3 期
Study of the Efficacy of Lurasidone in Cognitive Functioning in Bipolar PatientsBipolar DisorderNCT02731612Lakshmi N Yatham100
已完成
3 期
A 6 Month Safety and Efficacy Study of Once Daily Ciclesonide Hydrofluoroalkane (HFA) in the Treatment of Perennial Allergic Rhinitis (PAR) in Subjects 12 Years and OlderAllergic RhinitisPerennial Allergic RhinitisNCT00953147Sumitomo Pharma America, Inc.1,110